GIOVANNELLI, Simona
 Distribuzione geografica
Continente #
NA - Nord America 2.634
EU - Europa 2.526
AS - Asia 1.255
SA - Sud America 198
AF - Africa 32
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.648
Nazione #
US - Stati Uniti d'America 2.592
IT - Italia 1.295
SG - Singapore 432
GB - Regno Unito 313
CN - Cina 291
IE - Irlanda 258
SE - Svezia 161
VN - Vietnam 145
BR - Brasile 140
HK - Hong Kong 140
DE - Germania 121
UA - Ucraina 71
FR - Francia 62
RU - Federazione Russa 62
FI - Finlandia 53
IN - India 44
NL - Olanda 41
TR - Turchia 33
BD - Bangladesh 31
BG - Bulgaria 24
KR - Corea 24
ID - Indonesia 20
AR - Argentina 19
CA - Canada 19
MX - Messico 18
IQ - Iraq 15
LT - Lituania 13
MY - Malesia 9
PL - Polonia 9
CO - Colombia 8
EG - Egitto 8
ES - Italia 8
IR - Iran 8
ZA - Sudafrica 8
EC - Ecuador 7
PK - Pakistan 7
VE - Venezuela 7
AL - Albania 6
CL - Cile 6
JP - Giappone 6
PH - Filippine 6
SA - Arabia Saudita 6
AE - Emirati Arabi Uniti 5
CH - Svizzera 5
UZ - Uzbekistan 5
JO - Giordania 4
KE - Kenya 4
PT - Portogallo 4
PY - Paraguay 4
TW - Taiwan 4
UY - Uruguay 4
AT - Austria 3
AZ - Azerbaigian 3
BE - Belgio 3
CZ - Repubblica Ceca 3
IL - Israele 3
MA - Marocco 3
TH - Thailandia 3
AU - Australia 2
BO - Bolivia 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
HU - Ungheria 2
LB - Libano 2
NG - Nigeria 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
AM - Armenia 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
EU - Europa 1
GF - Guiana Francese 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
ME - Montenegro 1
MZ - Mozambico 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
SC - Seychelles 1
TJ - Tagikistan 1
TN - Tunisia 1
ZW - Zimbabwe 1
Totale 6.648
Città #
Singapore 283
Santa Clara 265
Dublin 256
Ashburn 248
Chandler 201
Southend 193
Fairfield 184
Woodbridge 141
Hong Kong 136
Dearborn 134
San Jose 133
Jacksonville 114
Milan 109
Nyköping 98
Beijing 93
Rome 92
Houston 85
Ann Arbor 84
New York 77
Seattle 70
Wilmington 66
Cambridge 62
London 52
Ho Chi Minh City 42
Helsinki 35
Naples 35
Hanoi 34
Council Bluffs 33
Bologna 32
Bari 30
Los Angeles 29
Munich 29
The Dalles 28
Hefei 25
Florence 24
Palermo 24
Izmir 22
Princeton 22
Turin 22
Eugene 21
Modena 21
Sofia 21
Lauterbourg 19
San Diego 19
Seoul 18
Dong Ket 16
Genoa 15
Jakarta 15
Shanghai 15
Moscow 14
Orem 12
Phoenix 12
Catania 11
São Paulo 11
Vicenza 11
Chicago 10
Denver 10
Pisa 10
Boardman 9
Bremen 9
Guangzhou 9
Padova 9
Chennai 8
Dallas 8
Ferrara 8
Perugia 8
Redondo Beach 8
Venice 8
Verona 8
York 8
Brescia 7
Brooklyn 7
Buffalo 7
Columbus 7
Fremont 7
Haiphong 7
San Mateo 7
Trieste 7
Ancona 6
Atlanta 6
Cagliari 6
Monte Porzio 6
Norwalk 6
Porto Alegre 6
Redwood City 6
Reggio Emilia 6
Turku 6
Des Moines 5
Frankfurt am Main 5
Hải Dương 5
Lecce 5
Montreal 5
Sassari 5
Tirana 5
Tokyo 5
Toronto 5
Warsaw 5
Augusta 4
Bergamo 4
Bitritto 4
Totale 4.195
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.129
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 475
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 413
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 368
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 363
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 362
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 357
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 319
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 306
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 297
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 253
Biomarker expression and survival after primary chemotherapy for breast cancer. 235
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 220
Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives 214
LAPATINIB IN ASSOCIAZIONE A CAPECITABINA IN PAZIENTI CON CARCINOMA MAMMARIO METASTTICO HER2 POSITIVO IN PROGRESSIONE DOPO TERAPIA CON TRASTUZUMAB 212
IMPROVED SURVIVAL AFTER RADIOTHERAPY FOR BRAIN METASTASES IN PATIENTS WITH HER2 POSITIVE BREAST TUMORS 210
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVE: ANALISI PRELIMINARE DELLE TOSSICITA’ 209
Operable Breast Cancer: preliminary results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy +/- gefitinib with biomarkers evaluation 196
CARCINOMI MAMMARI HER2 POSITIVI: CASISTICA DI MODENA 195
CHEMOTHERAPY-INDUCED MODULATION OF BIOMARKERS EXPRESSION IN PRIMARY BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 185
VALUTAZIONE DEL RISCHIO DI TOSSICITA’ CARDIACA DI TRASTUZUMAB IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO IN TRATTAMENTO ADIUVANTE 153
Totale 6.671
Categoria #
all - tutte 18.638
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.638


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202197 0 0 0 0 0 0 0 0 0 28 40 29
2021/2022381 8 49 53 13 7 23 20 9 50 16 88 45
2022/2023866 81 76 29 64 52 67 13 48 310 30 59 37
2023/2024766 36 45 44 48 82 68 53 111 38 69 88 84
2024/20251.328 57 65 45 129 220 193 80 96 171 66 74 132
2025/20261.744 128 67 123 228 340 132 243 97 181 205 0 0
Totale 6.671